Vermillion, Inc.'s OVA1® has received a new statement on clinical validation and medical use issued by the Society of Gynecologic Oncology (SGO). Citing peer-reviewed publications from two pivotal ...

A paper published in the June issue of Obstetrics & Gynecology demonstrated that adding OVA1 to a physician's preoperative assessment of a woman's ovarian mass would identify more ovarian cancers than ...

A study published online ahead of print in the June 2011 edition of Obstetrics & Gynecology demonstrated that American College of Obstetrics and Gynecology (ACOG) guidelines for determining the ...

"We are pleased to expand the in-network coverage for OVA1 with the signing of these agreements," said Fred Ferrara, Chief Operating Officer of Vermillion, Inc. "These agreements increase coverage in ...

Replacing CA125 with the OVA1 multivariate index assay may better predict whether an ovarian mass is cancerous in premenopausal women and those with early-stage disease, according to data from a study ...

MADISON, N.J. and FREMONT, Calif., March 9 OVA1(TM), the first blood test cleared by the U.S. Food and Drug Administration (FDA) for aiding in the pre-surgical evaluation of a woman's ovarian mass for ...

MADISON, N.J. and AUSTIN, Texas, May 12, 2011 /PRNewswire/ -- A study published online ahead of print in the June 2011 edition of Obstetrics & Gynecology demonstrated that American College of ...

A new study of OVA1 clinical performance in the presurgical detection of ovarian cancer, entitled "Clinical Performance of a Multivariate Index Assay For Detecting Early-Stage Ovarian Cancer," has ...

AUSTIN, Texas, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development and commercialization of ...

- Milestone data announced during Ovarian Cancer Awareness Month, which demonstrates OVA1’s superior sensitivity of ovarian cancer risk detection in both Caucasian and African American women versus ...

AUSTIN, Texas, June 10, 2020 (GLOBE NEWSWIRE) -- Vermillion, Inc. (VRML), a bioanalytical-based women’s health company focused on gynecologic disease, is excited to announce that its wholly-owned ...